Novartis to Appeal CAFC’s ‘Unprecedented’ U-Turn in Ruling on Multiple Sclerosis Drug Claims to SCOTUS

“Without hyperbole, this procedural insanity is literally unprecedented.”- Gene Quinn

Novartis - https://depositphotos.com/100383942/stock-photo-legal-questions-concept.htmlNovartis Pharmaceuticals announced today that it will appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S. Supreme Court, after the CAFC denied its request to rehear the case.

The CAFC in June vacated a different three-judge panel’s January opinion upholding Novartis’ U.S. Patent No. 9,187,405. In the original ruling, Chief Judge Moore had dissented from the majority; in the rehearing, Moore authored the opinion vacating the January decision, with Judge Linn dissenting.

The January decision had affirmed the District of Delaware’s final judgment that Novartis’ patent claims covering the multiple sclerosis treatment were not invalid for failing to satisfy the written description requirement under 35 U.S.C. § 112. In the June decision, the panel majority noted that adequate written description for a negative claim limitation exists when “the specification describes a reason to exclude the relevant [element],” citing to the Federal Circuit’s 2012 per curiam ruling in Santarus, Inc. v. Par Pharmaceutical, Inc. “Silence is generally not disclosure,” wrote Chief Judge Moore, reiterating a point she raised in her January dissent.

The January precedential decision, authored by Judge O’Malley and joined by Judge Linn, ruled in favor of Novartis, with Chief Judge Moore dissenting. Subsequently, after receiving a three-week extension, HEC filed a request for panel rehearing, with Novartis filing a response thereafter. One week after Novartis filed its response, Judge O’Malley retired. Judge Hughes was assigned to consider the request for panel rehearing along with Judge Linn and Chief Judge Moore, and despite not being a member of the original panel, Judge Hughes agreed with Chief Judge Moore that a panel rehearing should be ordered. Upon panel rehearing, Chief Judge Moore’s dissenting view became the majority opinion, with Judge Linn this time dissenting.

Weighing in on the June decision, IPWatchdog Founder and CEO Gene Quinn said in August that “[w]ithout hyperbole, this procedural insanity is literally unprecedented.” He noted that Novartis’ brief asking for panel rehearing, and alternatively for en banc review, pointed out that the Federal Circuit is the only Court of Appeals in the country that does not have a rule that requires at least one member of the majority to vote for a panel rehearing to be ordered.

In today’s statement, Novartis said that it expects FY 2022 sales to be negatively impacted by USD 300 million if generics launch in the United States. It added: “Previously, Novartis entered into settlement agreements with a number of ANDA filers. Under these settlements, those ANDA filers would have been able to launch a generic version of Gilenya, if approved by FDA, on an agreed upon date that is prior to the expiration of the dosing regimen patent, or earlier than the agreed upon date under certain circumstances. With this decision, HEC and other ANDA filers with FDA approval will potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions.”

Quinn in August said that the January O’Malley-Linn majority ruling “makes perfect sense to anyone familiar with the written description law because it is perfectly consistent with the Federal Circuit’s en banc ruling in [Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010)], which requires the analysis of the sufficiency of the disclosure to be viewed through the eyes of one of skill in the art.” He said that Chief Judge Moore’s analysis “adopted a new limitation on disclosure that has no prior basis in law, and in fact directly contradicts the Federal Circuit’s en banc ruling in [Ariad].”

Quinn added: “When something like this happens, the arbitrary nature of the crapshoot that is an appeal to the Federal Circuit is undeniably, and rather disgustingly, displayed out in the open for even casual observers to see.”

 

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Join the Discussion

5 comments so far. Add my comment.

  • [Avatar for Pro Say]
    Pro Say
    September 21, 2022 06:07 pm

    Hey! Was that a kangaroo that just hopped through the CAFC?!

  • [Avatar for Greg DeLassus]
    Greg DeLassus
    September 21, 2022 03:26 pm

    Much luck to them. Somehow, I do not like their chances.

  • [Avatar for Eileen McDermott]
    Eileen McDermott
    September 21, 2022 02:22 pm

    Clarified.

  • [Avatar for Ben]
    Ben
    September 21, 2022 01:36 pm

    >[Novartis] will appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) denial of its request to rehear a June decision

    Novartis’ press release says it will file a petition for certiorari with the Supreme Court on the underlying question. The decision to deny rehearing is not appealable, and is not what Novartis is asking the Supreme Court to review.

  • [Avatar for Loozap]
    Loozap
    September 21, 2022 01:12 pm

    That’s great

Add Comment

Your email address will not be published.